mRNA-1273 Variant-containing Formulation — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-31 in 3mo
ESTIMATED |
READOUT
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-co
Phase 4 · SARS-CoV-2 |
ModernaTX, Inc. | mRNA-1273 Variant-containing Formulation |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|